Abstract:Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with a high unmet medical need. The prevalence of HS reported in most studies is 1-2%, although it is likely to be under-reported and estimates vary globally owing to variance in data collection methods, ethnicity, geographical location and under-diagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses and draining tunnels commonly affecting the axillary, anogenital, inguinal and perianal/gluteal areas. Over time, chronic uncontrolled inflammation results in irreversible tissue destruction and scarring. Although the pathophysiology of HS has not been fully elucidated, the tumour necrosis factor (TNF)-α and interleukin (IL)-17 pathways have an important role, involving multiple cytokines. Currently, treatment options include topical medications; systemic therapies, including repeated and/or rotational courses of systemic antibiotics, retinoids and hormonal therapies; and various surgical procedures. The anti-TNF-α antibody adalimumab is currently the only biologic approved by both the US Food and Drug Administration and the European Medicines Agency for HS; however, its efficacy varies, with a clinical response reported in approximately 50% of patients in phase III trials. HS is a rapidly evolving field of discovery, with a diverse range of agents with distinct mechanisms of action currently being explored in clinical trials. Several other promising therapeutic targets have recently emerged, and agents targeting the IL-17 and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathways are the most advanced in ongoing or completed phase III clinical trials. Alongside limited therapeutic options, significant challenges remain in terms of diagnosis and disease management, with a need for better treatment outcomes. Other unmet needs include significant diagnostic delays, thus missing the therapeutic 'window of opportunity'; the lack of standardized outcome measures in clinical trials; and the lack of established, well-defined disease phenotypes and biomarkers.

An Atlas of the Hidradenitis Suppurativa Transcriptome

Hidradenitis Suppurativa from a Multi-Omic Scope

Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment

Comprehensive Catalog of Variants Potentially Associated with Hidradenitis Suppurativa, Including Newly Identified Variants from a Cohort of 100 Patients

Cytokine-Mediated Molecular Pathophysiology of Hidradenitis Suppurativa: A Narrative Review

Cellular indexing of transcriptomes and epitopes (CITE-Seq) in hidradenitis suppurativa identifies dysregulated cell types in peripheral blood and facilitates diagnosis via machine learning

Microbiome in Hidradenitis Suppurativa-What We Know and Where We Are Heading

Identification of Novel Genetic Risk Variants Associated with Hidradenitis Suppurativa in an Exome Sequencing Cohort of 92,455 Individuals

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

Insights into Gut Microbiome Composition in Hidradenitis Suppurativa: A Comprehensive Examination of Dietary Habits and Environmental Influences

Single-Cell RNA Sequencing Reveals Cellular and Transcriptional Changes Associated With M1 Macrophage Polarization in Hidradenitis Suppurativa

A Novel Whole Tissue Explant Model of Hidradenitis Suppurativa

Identification of hub-genes, lncRNAs, and skin cancer inducer genes through meta-analysis of Hidradenitis Suppurativa disease transcriptome data.

The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa-Light at the End of the Microbiological Tunnel

Epidemiology of Hidradenitis Suppurativa: Current Status

LncRNA microarray profiling identifies novel circulating lncRNAs in hidradenitis suppurativa

Hidradenitis Suppurativa: Comprehensive Review of Predisposing Genetic Mutations and Changes

Hidradenitis suppurativa: a new therapeutic approach for an old disease

Interleukin-1 family cytokines and soluble receptors in hidradenitis suppurativa

Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling

Hidradenitis suppurativa: infection, autoimmunity, or both?